Slide 1: Eisai Inc.
Ramzi Ayyad Nita Silimkhan Sean Ryan
Slide 2: Mission, Vision, Values
Human Health Care (HHC) mission
Also Florence Nightingale's signature Innovative solutions for preventive care Cure and care for health and well being worldwide
Vision: responsible, focused, efficient, innovative and solution-oriented pharma company. Values: Integrity, respect, professionalism, quality, and teamwork.
Slide 3: Eisai Corporation: A Global Company
Founded as Nihon Eisai Co. in Japan in 1941. Current headquarters in Tokyo Japan More than 9,000 employees worldwide 40 subsidiaries and 2 Joint Ventures worldwide.
Joint Ventures:
Wholly Owned Subsidiaries present in 19 countries:
Bracco Corporation (Italian Company), P.T. Indonesia.
North America : U.S.A (5 sites) Europe: U.K., Sweden, Germany, France, Italy, Switzerland, Spain, Netherlands Asia: Japan, Indonesia, Taiwan, China, India, Malaysia, Singapore, Philippines, South Korea, Thailand
Slide 4: Eisai Inc. of North America
Eisai first established in the U.S. in 1981 Headquarters in Woodcliff Lake, NJ as of 2007
Chairman and CEO : Hajime Shimizu President and COO : Lonnel Coats VP Business Development: Alex Scott VP Finance and CFO: Kenneth R (Ken) Klauser VP and General Counsel: Douglas B. Snyder VP Sales and Marketing: Frank Ciriello
Research Facilities:
Eisai Medical Research Inc., Ridgefield NJ Eisai Research Institute of Boston, Andover, Ma Eisai Inc./ RTP, Research Triangle Park, NC Eisai Machinery : Pharmaceutical Machinery Sales
Other:
Slide 5: Eisai’s Alliance/Acquisitions History in the U.S.
1994 -- agreement with Pfizer Inc to co-promote Aricept® 1997 -- agreement with Janssen Pharmaceuticals Inc. to co-promote Aciphex® 2002 -- acquires Cerebyx from Warner Lambert company. 2003 -- agreement with Teva Pharmaceuticals to co-promote rasagiline. 2004 -- acquires anti-epileptic drug Zonegran® from Elan Corporation 2006 -- acquires four oncology-related products from Ligand Pharmaceuticals. 2007 –- acquires Morphotek biopharmaceutical company
Slide 6: Eisai Inc.: Inside the numbers
Ticker Symbol: ESALY Apr 11th 2008 price: $34.45 Traded as ADR on NYSE Osaka Securities Exchange Tokyo Stock Exchange
Eisai 5 year stock performance on NYSE
Slide 7: Financial Highlight Comparison
Eisai
Sales Revenue* Income* Sales Growth* Income Growth Net Profit Margin* R&D expense per Revenue* Dividend and yield Market Cap EPS* Forward P/E *Last 12 months
1
Pfizer
48.42 billion 8.21 billion 0.10% 82.10% 17.05% 16.71%1 1.17 (6.26%) 138.32 billion 1.17 8.6
Wyeth
22.4 billion 4.62 billion 10.10% 18.90% 20.61% 14.5%1 1.12(2.49%) 60.80 billion 3.37 13.1
6.67 billion 6.98 million 12.10% 3.50% 10.50% 13% 1.18 (3.42%) 9.79 billion 2.45 13.8
FY 2007 Income Statement
SOURCE: MSN Money
Slide 8: Percent Growth Rate
Growth Rates %
Sales (Qtr vs year ago qtr) Net Income (YTD vs YTD) Net Income (Qtr vs year ago qtr) Sales (5-Year Annual Avg.) Net Income (5-Year Annual Avg.) Dividends (5-Year Annual Avg.)
Eisai
8.5 17.3 3.5 9.32 14.1 32.85
Industry
39.4 61.5 46.2 36.68 45.57 1.22
S&P 500
16.2 14.6 8.6 13.88 20.41 11.89
Source : MSN Money
Slide 9: Liquidity Ratio Comparisons
Financial Condition
Debt/Equity Ratio Current Ratio Quick Ratio Interest Coverage Leverage Ratio Book Value/Share
Company
0.04 2.1 1.8 NA 1.5 19.9
Industry
0.5 3.4 3.1 360.9 1.9 8.34
S&P 500
1.4 1.2 0.9 49.3 4.6 21.59
Source : MSN Money
Slide 10: Profitability Ratios
Investment Returns %
Return On Equity Return On Assets Return On Capital Return On Equity (5-Year Avg.) Return On Assets (5-Year Avg.) Return On Capital (5-Year Avg.)
Company
13.2 9.2 12.4 12.5 8.6 11.4
Industry
7.6 3 5.5 -0.9 2.5 2.9
S&P 500
25.5 8.2 10.9 20.8 7.5 10
Source : MSN Money
Slide 11: Eisai Recent News
Development of Parkinson disease drug, Perampanel (E 2007), was halted after failing late-stage drug trial.
(Bloomberg.com)
Eisai won a court battle barring Teva pharmaceutical from selling the Alzheimer drug, Aricept, which accounts for 40% of the company’s revenues . (Bloomberg.com) Eisia to resume clinical trial studies on E2012, an alzheimer drug.
(pharmalive.com).
FDA approved Aloxi injection for post operative nausea and vomiting (Eisai press release, 3/02/08)
Slide 12: Eisai’s Pharmaceuticals
Two major moneymakers Aricept Aciphex Three others Cerebryx Zonegran Fragmin
Slide 13: Aricept
improves cognition for Alzheimer’s disease - oral Sales from 75 countries (but not England) Best pill on the market, but far from a miracle pill Off-patent: November 2010
Slide 14: Aciphex
Proton pump inhibitor, for GERD (gastroesophageal reflux disease) - oral Co-marketed with PriCara (Ortho-McNeil, part of J&J) in U.S.; marketed as Pariet outside U.S. Also approved for treatment of ulcers w/antibiotics (2002) Off-patent: May 2013
Slide 15: Fragmin
Clot-buster - injectable Bought U.S. rights from Pfizer Stops deep-vein thrombosis (DVT) which can lead to pulmonary edema (PE) Also approved for angina w/aspirin Low-molecular-weight heparins – general heparin problems with Chinese suppliers
Slide 16: Eisai’s Seizure Portfolio
Cerebyx – seizure control - injectable -Owned by Pfizer, marketed by Eisai via hospital-based sales force
Zonegran – seizure medication - oral -Bought from Elan
Slide 17: Eisai’s Oncology Portfolio
ONTAK Targretin (capsules) Targretin (gel) Panretin (gel)
Slide 18: Eisai’s Research Focus
Neurology Gastrointestinal disorders Cancer Acute Care
Slide 19: The Eisai Research Pipeline Phase I Compounds
E5555 – Critical care acute coronary syndrome Aciphex – Gastrointestinal disorder extended release formulation E7080 – Cancer oral anti-cancer agent E7974 – Cancer E7820 - Cancer
Slide 20: The Eisai Research Pipeline Phase II Compounds
AS-3201 – Diabetic Neuropathy E7389 – Cancer non small cell lung cancer E2007 – Neurology-migraine prevention Aciphex – Gastrointestinal disorder, pediatric use Aciphex - Gastrointestinal disorder, intermittent therapy for symptomatic gastroesophageal reflux disease
Slide 21: The Eisai Research Pipeline Phase II Compounds (cont.)
E7389 – Breast cancer E2007 – Neurology-epilepsy E7389 – Prostate cancer
Slide 22: The Eisai Research Pipeline Phase III/Submission to FDA
E5564 – Critical care-severe sepsis Rufinamide – epilepsy Aricept – Severe Alzheimer’s disease
